Fig. 3
In vitro anti-tumor effect analysis of BDM. (A) Schematic diagram of the in vitro anti-tumor assay of BDM. (B) The cell viability of SCC7 stimulated with decitabine under different concentrations following the instruction (n = 3 per group, two-way ANOVA with Dunnett’s multiple comparisons test was used). (C) The cell viability of SCC7 under different treatments (n = 3 per group, one-way ANOVA with Dunnett’s multiple comparisons test was used). (D) Immunofluorescence images of live/dead staining of SCC7 cells with or without 808 nm (1.5 W/cm2, 5 min) and 660 nm (150mW, 5 min) laser irradiation treatment. Scale bar = 100 μm. (E) Immunofluorescence images of ROS staining of SCC7 cells with or without 660 nm (150mW, 5 min) laser irradiation treatment. Scale bar = 50 μm. (F) Immunofluorescence images of HMGB1 and CRT expression on SCC7 cells with BDM nanoparticles (80 µg/mL) co-incubation under 808 nm (1.5 W/cm2, 5 min) and 660 nm (150mW, 5 min) laser irradiation treatment. Scale bar = 50 μm. (G-H) Cell cycle related flow cytometry analysis of SCC7 treated for 24 h (G1: Con, G2: BP, G3: BD, G4: BDM). The distribution of cells in G1, S, G2 phase (n = 3 per group, two-way ANOVA with Dunnett’s multiple comparisons test was used). All experiments were independently repeated in triplicate. (**, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant)